5 active not recruiting, 3 completed, 2 recruiting, 2 unknown. 14 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Active not recruiting 5, Completed 3, Recruiting 2, Unknown 2, Not yet recruiting 1, Terminated 1 |
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Unknown 1 |
Follow Chronic Myeloid Leukemia (CML): new trials by email Literature Review of Chronic Myeloid Leukemia (CML) trials Research Report on Chronic Myeloid Leukemia (CML)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Asciminib Frontline Risk Adapted Dasatinib 80mg QD (5 days per week), Standarc of Care - Chronic Myeloid Leukemia (CML) | Phase 2 | Not yet recruiting | Prof. Dr. med. Andreas Hochhaus | 200 | 2027-01-01 | 2026-09-04 |
| Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations asciminib 200 mg BID - Chronic Myeloid Leukemia (CML) | Phase 2 | Active not recruiting | Thomas Ernst, PD Dr. med. | 50 | 2026-06-22 | 2026-08-27 |
| Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy Imatinib, Artesunate - Chronic Myeloid Leukemia (CML) | Phase 2 | Active not recruiting | Obafemi Awolowo University | 75 | 2025-07-01 | 2026-10-14 |
| Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib. ABL001/Asciminib - Chronic Myeloid Leukemia (CML) | Phase 2 | Recruiting | Novartis Pharmaceuticals | 20 | 2025-02-18 | 2026-04-21 |
| A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies Ossium HPC Marrow, Bone Marrow Transplant, Pre-transplant conditioning - Myeloablative (MAC), Pre-transplant conditioning - Reduced Intensity (RIC) - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Ossium Health, Inc. | 12 | 2024-08-16 | 2026-09-10 |
| Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia Ponatinib 15mg QD, Ponatinib 30mg QD - Chronic Myeloid Leukemia (CML) | Phase 2 | Unknown | Associazione Italiana Pazienti Leucemia Mieloide Cronica | 50 | 2021-02-01 | 2021-02-03 |
| TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies Cyclophosphamide, Fludarabine, Thiotepa - Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML) | Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 69 | 2019-01-31 | 2026-09-15 |
| Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors Hyperfractionated total body irradiation, Thiotepa, Cyclophosphamide - Acute Lymphoid Leukemia (ALL), Acute Myeloid Leukemia (AML) | Phase 2 | Terminated | Memorial Sloan Kettering Cancer Center | 9 | 2018-07-25 | 2025-04-06 |
| Second STOP After Pioglitazone Priming in CML Patients Pioglitazone + TKI - Chronic Myeloid Leukemia (CML) | Phase 2 | Recruiting | Versailles Hospital | 26 | 2016-12-01 | 2026-07-06 |
| Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation Anti-thymocyte globulin (rabbit), Blinatumomab, Cyclophosphamide - Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML) | Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 170 | 2016-07-14 | 2025-08-12 |
| CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide - Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML) | Phase 1 / Phase 2 | Unknown | Diane George | 14 | 2013-06-03 | 2024-06-04 |
| A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) ponatinib - Phase 1, ponatinib - Phase 2 - Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) | Phase 1 / Phase 2 | Completed | Ariad Pharmaceuticals | 35 | 2012-08-31 | 2022-06-13 |
| Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers WT1:126-134, PR1:169-177 Peptide, GM-CSF (Sargramostim) - Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 10 | 2007-06-01 | 2021-07-12 |
| Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy WT1 Peptide Vaccine - Myelodysplastic Syndrome, Acute Myeloid Leukemia (AML) | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 4 | 2007-02-01 | 2014-07-08 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (14) · Leukemia, Myeloid, Acute (7) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Myelodysplastic Syndromes (5) · Hodgkin Disease (3) · Leukemia (3) · Leukemia, Myelomonocytic, Juvenile (3) · Lymphoma, Non-Hodgkin (3) · Hematologic Diseases (2) · Lymphoma (2) · Acquired Immunodeficiency Syndrome (1) · Anemia, Aplastic (1) · Anemia, Diamond-Blackfan (1) · Anemia, Refractory, with Excess of Blasts (1) · Anemia, Sickle Cell (1)
Chronic Disease (14) · Disease Attributes (14) · Hemic and Lymphatic Diseases (14) · Pathologic Processes (14) · Pathological Conditions, Signs and Symptoms (14) · Bone Marrow Diseases (13) · Leukemia, Myeloid (13) · Myeloproliferative Disorders (13) · Neoplasms (13) · Neoplasms by Histologic Type (13) · Hematologic Diseases (12) · Leukemia (11) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Leukemia, Lymphoid (6)
Cyclophosphamide (5) · Melphalan (5) · Thiotepa (4) · fludarabine (4) · fludarabine phosphate (4) · Filgrastim (3) · Mesna (3) · Busulfan (2) · Granulocyte Colony-Stimulating Factor (2) · Rituximab (2) · Tacrolimus (2) · asciminib (2) · blinatumomab (2) · ponatinib (2) · thymoglobulin (2)
National Heart, Lung, and Blood Institute (NHLBI) (2) · St. Jude Children's Research Hospital (2) · Ariad Pharmaceuticals (1) · Associazione Italiana Pazienti Leucemia Mieloide Cronica (1) · Diane George (1) · Memorial Sloan Kettering Cancer Center (1) · Novartis Pharmaceuticals (1) · Obafemi Awolowo University (1) · Ossium Health, Inc. (1) · Prof. Dr. med. Andreas Hochhaus (1) · Thomas Ernst, PD Dr. med. (1) · Versailles Hospital (1)
United States (7) · France (2) · Germany (2) · Italy (1) · Japan (1) · Nigeria (1)
Brandon Triplett, MD (2) · Brian Shaffer, MD (1) · Carlo Gambacorti (1) · Diane George, MD (1) · Dr. B. A. Adeagbo (1) · John Barrett, MD (1) · Minocher Battiwalla, MD (1) · Prof. R. A. Bolarinwa (1)
PMID 21134985, PMID 22198310, PMID 28444644, PMID 34699069
2018 (1), 2025 (1)